Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | NOS3 | P29474 | 4/20 | 0.37 |
| ▸ | NOS2 | P35228 | 4/20 | 0.37 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CHKA | P35790 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL31336857 | 0.97 | HTT (0.37) | HTTHSD17B10NOS3NOS2TLR7 | |
| SCHEMBL28372517 | 0.80 | HTT (0.35) | HTTHSD17B10NOS3NOS2 | |
| SCHEMBL29350976 | 0.80 | HTT (0.35) | HTTHSD17B10NOS3NOS2 | |
| SCHEMBL30154882 | 0.74 | NOS3 (0.36) | NOS3NOS2NUDT1NOS1 | |
| SCHEMBL4569228 | 0.74 | NOS3 (0.36) | NOS3NOS2NUDT1NOS1 | |
| SCHEMBL16992858 | 0.72 | HTT (0.49) | HTTHSD17B10NOS3NOS2POLB | |
| Hydrochloric Acid SCHEMBL16992973 | 0.70 | HTT (0.47) | HTTHSD17B10NOS3NOS2POLB | |
| SCHEMBL29985108 | 0.69 | — | — | |
| SCHEMBL1024624 | 0.69 | — | — | |
| SCHEMBL670030 | 0.69 | HTT (0.37) | HTTCA2CHKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4688155-A1 | MORPHOLINE OREXIN RECEPTOR ANTAGONISTS | Bial-Portela & CA, S.A. (PT) | 2026-02-11 | — | — | EP | claimed |
| WO-2025125665-A1 | FURTHER SUBSTITUTED IMIDAZOLES AS INHIBITORS OF NAV1.8 | Grünenthal GmbH (DE) | 2025-06-19 | — | — | WO | claimed |
| WO-2025023852-A1 | MORPHOLINE OREXIN RECEPTOR ANTAGONISTS | BIAL - PORTELA & CA., S.A. (PT) | 2025-01-30 | — | — | WO | claimed |
| EP-4028393-A1 | 3, 5-DISUBSTITUTED PYRAZOLE COMPOUNDS AS KINASE INHIBITORS AND USES THEREOF | Impact Therapeutics (Shanghai), Inc (CN) | 2022-07-20 | — | — | EP | claimed |
| WO-2021043208-A1 | 3, 5-DISUBSTITUTED PYRAZOLE COMPOUNDS AS KINASE INHIBITORS AND USES THEREOF | IMPACT THERAPEUTICS, INC (CN) | 2021-03-11 | — | — | WO | claimed |
| US-20250388553-A1 | AMINOPYRAZINE DERIVATIVES AS PI3K-y INHIBITORS | INCYTE CORP (US) | 2025-12-25 | — | — | US | disclosed |
| US-12503467-B2 | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors | IDEAYA BIOSCIENCES, INC. (US) | 2025-12-23 | — | — | US | disclosed |
| US-20250313550-A1 | AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS | INCYTE CORPORATION | 2025-10-09 | — | — | US | disclosed |
| US-12421197-B2 | Aminopyrazine derivatives as PI3K-γ inhibitors | INCYTE CORPORATION (US) | 2025-09-23 | — | — | US | disclosed |
| US-12365668-B2 | Aminopyrazine diol compounds as PI3K-y inhibitors | INCYTE CORPORATION (US) | 2025-07-22 | — | — | US | disclosed |
| CN-115925697-B | Small molecule immunoregulation inhibitor and pharmaceutical composition and application thereof | 昆药集团股份有限公司 | 2025-05-09 | — | — | CN | disclosed |
| US-12281101-B2 | Bicyclic lactams and methods of use thereof | GENENTECH, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| WO-2019057724-A1 | PYRAZINE-4CARBAMATE OR -UREA DERIVATIVES AS HERBICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2019-03-28 | — | — | WO | disclosed |
| EP-3317269-A1 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | H. Hoffnabb-La Roche Ag (CH) | 2018-05-09 | — | — | EP | disclosed |
| WO-2017004500-A9 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | WO | disclosed |
| US-9776967-B2 | Carboxamide derivatives as pesticidal compounds | BAYER ANIMAL HEALTH GMBH (DE) | 2017-10-03 | — | — | US | disclosed |
| US-20170044104-A1 | NEW PESTICIDAL COMPOUNDS AND USES | BAYER ANIMAL HEALTH GMBH (DE) | 2017-02-16 | — | — | US | disclosed |
| US-20170008877-A1 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-01-12 | — | — | US | disclosed |
| WO-2017004500-A1 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-01-05 | — | — | WO | disclosed |
| CN-103946221-B | heterocyclic compounds for the treatment of cystic fibrosis | 诺华股份有限公司 | 2016-08-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12421197-B2 | Aminopyrazine derivatives as PI3K-γ inhibitors | PIK3R5, PIK3CD, PIK3CG | HTT 1262/4885HSD17B10 2423/4885NOS3 1333/4885 |
| US-12281101-B2 | Bicyclic lactams and methods of use thereof | LSS, LPXN, CYP1B1 | HTT 4818/4885HSD17B10 942/4885NOS3 3864/4885 |
| US-20250388553-A1 | AMINOPYRAZINE DERIVATIVES AS PI3K-y INHIBITORS | PIK3R5, PIK3R1, PIK3C2B | HTT 623/4885HSD17B10 1800/4885NOS3 1396/4885 |
| US-12365668-B2 | Aminopyrazine diol compounds as PI3K-y inhibitors | PIK3CD, PIK3R5, PIK3CG | HTT 1840/4885HSD17B10 2011/4885NOS3 1517/4885 |
| US-20170008877-A1 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | LSS, LPXN, CYP1B1 | HTT 4818/4885HSD17B10 942/4885NOS3 3864/4885 |
| US-20170044104-A1 | NEW PESTICIDAL COMPOUNDS AND USES | ACHE, DDT, DNPH1 | HTT 238/4885HSD17B10 3166/4885NOS3 3231/4885 |
| US-20250313550-A1 | AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS | PIK3CD, PIK3R5, PIK3CG | HTT 1840/4885HSD17B10 2011/4885NOS3 1517/4885 |
| US-12503467-B2 | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors | MAT2B, MAT2A, MAT1A | HTT 4088/4885HSD17B10 3051/4885NOS3 1325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.